VAPO Stock Overview
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.04|
|52 Week High||US$31.87|
|52 Week Low||US$2.81|
|1 Month Change||-39.56%|
|3 Month Change||-80.12%|
|1 Year Change||-84.58%|
|3 Year Change||-82.61%|
|5 Year Change||n/a|
|Change since IPO||-81.00%|
Recent News & Updates
Vapotherm: Out Of Air
Vapotherm has seen a boom induced by the pandemic reverse violently. The pandemic has not boosted Vapotherm's business, as losses have only increased during this period of time. With revenues down to much lower levels and losses being very substantial, there are no (quick) fixes in sight.
|VAPO||US Medical Equipment||US Market|
Return vs Industry: VAPO underperformed the US Medical Equipment industry which returned -15.8% over the past year.
Return vs Market: VAPO underperformed the US Market which returned -15.1% over the past year.
|VAPO Average Weekly Movement||16.4%|
|Medical Equipment Industry Average Movement||10.5%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: VAPO is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: VAPO's weekly volatility has increased from 10% to 16% over the past year.
About the Company
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor, which provides compressed air necessary to run the precision flow systems; aerosol aeroneb adaptor to facilitate delivery of ultrasonic aerosolized medication; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol medication; and tracheostomy adaptors.
Vapotherm Fundamentals Summary
|VAPO fundamental statistics|
Is VAPO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|VAPO income statement (TTM)|
|Cost of Revenue||US$58.69m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.72|
|Net Profit Margin||-70.49%|
How did VAPO perform over the long term?See historical performance and comparison
Is Vapotherm undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate VAPO's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate VAPO's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: VAPO is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US Medical Equipment industry average.
PE vs Market: VAPO is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate VAPO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: VAPO is good value based on its Price-To-Book Ratio (1.5x) compared to the US Medical Equipment industry average (2.5x).
How is Vapotherm forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VAPO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: VAPO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: VAPO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: VAPO's revenue (13.2% per year) is forecast to grow faster than the US market (8% per year).
High Growth Revenue: VAPO's revenue (13.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if VAPO's Return on Equity is forecast to be high in 3 years time
How has Vapotherm performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VAPO is currently unprofitable.
Growing Profit Margin: VAPO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: VAPO is unprofitable, and losses have increased over the past 5 years at a rate of 14.1% per year.
Accelerating Growth: Unable to compare VAPO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VAPO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16.1%).
Return on Equity
High ROE: VAPO has a negative Return on Equity (-134.12%), as it is currently unprofitable.
How is Vapotherm's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: VAPO's short term assets ($125.8M) exceed its short term liabilities ($23.4M).
Long Term Liabilities: VAPO's short term assets ($125.8M) exceed its long term liabilities ($103.2M).
Debt to Equity History and Analysis
Debt Level: VAPO's net debt to equity ratio (43.7%) is considered high.
Reducing Debt: VAPO's debt to equity ratio has increased from 96.5% to 178.9% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VAPO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: VAPO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 12.7% each year
What is Vapotherm current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VAPO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VAPO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VAPO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VAPO's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as VAPO has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Joe Army (57 yo)
Mr. Joseph F. Army, also known as Joe, CPA has been the Chief Executive Officer and President of Vapotherm, Inc. since June 26, 2012. Mr. Army served as the Chief Executive Officer and President of Salient...
CEO Compensation Analysis
Compensation vs Market: Joe's total compensation ($USD3.44M) is above average for companies of similar size in the US market ($USD771.12K).
Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.
Experienced Management: VAPO's management team is considered experienced (3.8 years average tenure).
Experienced Board: VAPO's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: VAPO insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.5%.
Vapotherm, Inc.'s employee growth, exchange listings and data sources
- Name: Vapotherm, Inc.
- Ticker: VAPO
- Exchange: NYSE
- Founded: 1993
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$80.753m
- Shares outstanding: 26.56m
- Website: https://www.vapotherm.com
Number of Employees
- Vapotherm, Inc.
- 100 Domain Drive
- New Hampshire
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/26 00:00|
|End of Day Share Price||2022/05/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.